摘要
目的探讨不同剂量甲氨蝶呤联合放疗对弥漫大B细胞淋巴瘤患者疗效。方法根据随机数字表法将2019年9月-2020年5月65例弥漫大B细胞淋巴瘤患者作为研究对象,均给予放射治疗,同时小剂量组32例给予1g/m^(2)甲氨蝶呤,大剂量组33例给予3g/m^(2)甲氨蝶呤,比较两组患者临床疗效、肿瘤标志物水平、不良反应发生情况及生存率。结果大剂量组总有效率87.88%(29/33)高于小剂量组65.62%(21/32)(P<0.05);治疗后,两组乳酸脱氢酶(LDH)、甲胎蛋白(AFP)、癌胚抗原(CEA)表达水平均下降,大剂量组低于小剂量组(P<0.05);大剂量组不良反应发生率与小剂量组差异无统计学意义(P>0.05);大剂量组治疗后1年、2年的复发率低于小剂量组,2年生存率87.88%(29/33)高于小剂量组65.62%(21/32)(P<0.05)。结论对于弥漫大B细胞淋巴瘤患者通过给予大剂量3g/m^(2)甲氨蝶呤联合放疗能够抑制癌细胞的增长,提高治疗效果,降低复发率和提高生存率,不良反应的发生无明显变化。
Objective To investigate the effect of different doses of methotrexate combined with radiotherapy on patients with diffuse large B-cell lymphoma.Methods According to the random number table method,65 patients with diffuse large B-cell lymphoma from September 2019 to May 2020 were selected as the research objects.All patients were given radiotherapy and 32 patients in the low-dose group were given 1 g/m^(2)methotrexate,and 33 patients in the high-dose group were given 3 g/m^(2)methotrexate.The clinical eficacy,tumor marker levels,adverse reactions and survival rates were compared between the two groups.Results The total effective rate of high dose group was 87.88%(29/33),which was higher than that of low dose group 65.62%(21/32)(P<0.05).After treatment,the expression levels of lactate dehydrogenase(LDH),alpha-fetoprotein(AFP)and carcinoembryonic antigen(CEA)in the two groups were decreased,and the high-dose group was lower than the low-dose group(P<0.05).There was no significant difference in the incidence of adverse reactions between the high-dose group and the low-dose group(P>0.05).The 1-year and 2-year recurrence rates of the high-dose group were lower than those of the low-dose group,and the 2-year survival rate(87.88%,29/33)was higher than that of the low-dose group(65.62%,21/32)(P<0.05).Conclusion For patients with diffuse large B cell lymphoma,the administration of 3 g/m^(2)methotrexate combined with radiotherapy can inhibit the growth of cancer cells,improve the therapeutic effect,reduce the recurrence rate and improve the survival rate,and there is no significant change in the incidence of adverse reactions.
作者
姬利萍
邢国臣
柯洋
冯培贝
郭晓丹
易善永
JI Li-ping;XING Guo-chen;KE Yang;FENG Pei-bei;GUO Xiao-dan;YI Shan-yong(Department of Oncology,Zhengzhou Central Hospital Affiliated to Zhengzhou University,Zhengzhou,Henan,450007,China)
出处
《中国血液流变学杂志》
CAS
2023年第1期20-23,共4页
Chinese Journal of Hemorheology
关键词
剂量
甲氨蝶呤
放疗
弥漫大B细胞淋巴瘤
dose
methotrexate
radiotherapy
diffuse large B-cell lymphoma
